doi: 10.3389/fcell.2026.1816014 Received 23 February 2026 Revised 16 March 2026 Accepted 24 March 2026 Published 21 April 2026 Volume 14 - 2026 Edited by Sabrina Gohlke, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Germany Reviewed by Atefeh Rabiee, The University of the Pacific, United States Christa Buechler, University Medical Center Regensburg, Germany Updates Copyright 2026 Soni and Abbott
Selection is required to proceed
No early effect of intrathecal rituximab in progressive multiple sclerosis (EFFRITE Clinical Trial)
Monitoring is recommended in patients receiving regular injections or those with comorbid conditions
But I feel like Ive accomplished a lot, for an album I didnt feel like was my best and clearest vision of myself
XmAb5871 is an antibody that co-engages CD19 and the inhibitory FcRIIb receptor, resulting in B cell inhibition but not ablation ( Proteasome inhibitors The lack of expression of CD20 on plasma cells, especially long-lived plasma cells may be one of the reasons for the poor performance of anti-CD20 therapies in SLE ( Bortezomib is a proteasome inhibitor, that is efficacious in plasma cell cancers
